Effects of 15-month aldose reductase inhibition with Fidarestat (cas 136087-85-9) on the experimental diabetic neuropathy in rats

Add time:09/04/2019    Source:sciencedirect.com

We examined the effects of long-term treatment with an aldose reductase inhibitor (ARI) Fidarestat (cas 136087-85-9) on functional, morphological and metabolic changes in the peripheral nerve of 15-month diabetic rats induced by streptozotocin (STZ). Slowed F-wave, motor nerve and sensory nerve conduction velocities were corrected dose-dependently in fidarestat-treated diabetic rats. Morphometric analysis of myelinated fibers demonstrated that frequencies of abnormal fibers such as paranodal demyelination and axonal degeneration were reduced to the extent of normal levels by fidarestat-treatment. Axonal atrophy, distorted axon circularity and reduction of myelin sheath thickness were also inhibited. These effects were associated with normalization of increased levels of sorbitol and fructose and decreased level of myo-inositol in the peripheral nerve by fidarestat. Thus, the results demonstrated that long-term treatment with fidarestat substantially inhibited the functional and structural progression of diabetic neuropathy with inhibition of increased polyol pathway flux in diabetic rats.

We also recommend Trading Suppliers and Manufacturers of Fidarestat (cas 136087-85-9). Pls Click Website Link as below: cas 136087-85-9 suppliers

Prev:Long-term treatment with Fidarestat (cas 136087-85-9) suppresses the development of diabetic retinopathy in STZ-induced diabetic rats
Next:Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor Fidarestat (cas 136087-85-9) (SNK-860))